Majority of patients with inflammatory bowel disease in clinical remission have mucosal inflammation

Inflammatory Bowel Diseases

Volumn 18, Issue 9, 2012, Pages 1634-1640

  Baars, Judith E ^a   Nuij, Veerle J A A ^a   Oldenburg, Bas ^b   Kuipers, Ernst J ^a   Van Der Woude, Christien J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

clinical remission; inflammatory bowel disease; mucosal inflammation

Indexed keywords

ADULT; ARTICLE; COLONOSCOPY; CONTROLLED STUDY; CROHN DISEASE; DISEASE COURSE; DISEASE SEVERITY; DISEASE SURVEILLANCE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTESTINE MUCOSA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; REMISSION; ULCERATIVE COLITIS;

ADULT; COLONOSCOPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MUCOSITIS; PROGNOSIS; RECURRENCE; REMISSION INDUCTION; YOUNG ADULT;

EID: 84865041023     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21925     Document Type: Article

References (22)

1. Minderhoud IM, Samsom M, Oldenburg B,. What predicts mucosal inflammation in Crohn's disease patients? Inflamm Bowel Dis. 2007; 13: 1567-1572.
2. Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol. 2010; 105: 162-169.
3. Van Assche G, Vermeire S, Rutgeerts P,. The potential for disease modification in Crohn's disease. Nat Rev Gastroenterol Hepatol. 2010; 7: 79-85.
4. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology. 2004; 126: 402-413.
5. Rutgeerts P, Diamond RH, Bala M, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc. 2006; 63: 433-442.
6. Baert F, Moortgat L, Van Assche G, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology. 2010; 138: 463-468.
7. Froslie KF, Jahnsen J, Moum BA, et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. 2007; 133: 412-422.
8. Eaden JA, Mayberry JF,. Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease. Gut. 2002; 51 (Suppl 5): V10-V12.
9. Winawer S, Fletcher R, Rex D, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale€"update based on new evidence. Gastroenterology. 2003; 124: 544-560.
10. Van Assche G, Dignass A, Panes J, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. J Crohns Colitis. 2010; 4: 7-27.
11. Stange EF, Travis SP, Vermeire, et al. European evidence-based consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohns Colitis. 2008; 2: 1-23.
12. Cairns SR, Scholefield JH, Steele RJ, et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut. 2010; 59: 666-689.
13. Higgins PD, Schwartz M, Mapili J, et al. Is endoscopy necessary for the measurement of disease activity in ulcerative colitis? Am J Gastroenterol. 2005; 100: 355-361.
14. Floren CH, Benoni C, Willen R,. Histologic and colonoscopic assessment of disease extension in ulcerative colitis. Scand J Gastroenterol. 1987; 22: 459-462.
15. Moum B, Ekbom A, Vatn MH, et al. Change in the extent of colonoscopic and histological involvement in ulcerative colitis over time. Am J Gastroenterol. 1999; 94: 1564-1569.
16. Kiesslich R, Fritsch J, Holtmann M, et al. Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology. 2003; 124: 880-888.
17. Kleer CG, Appelman HD,. Ulcerative colitis: patterns of involvement in colorectal biopsies and changes with time. Am J Surg Pathol. 1998; 22: 983-989.
18. Riley SA, Mani V, Goodman MJ, et al. Microscopic activity in ulcerative colitis: what does it mean? Gut. 1991; 32: 174-178.
19. Geboes K, Ectors N, D'Haens G, et al. Is ileoscopy with biopsy worthwhile in patients presenting with symptoms of inflammatory bowel disease? Am J Gastroenterol. 1998; 93: 201-206.
20. Lichtenstein GR, Rutgeerts P,. Importance of mucosal healing in ulcerative colitis. Inflamm Bowel Dis. 2010; 16: 338-346.
21. Fausa O, Schrumpf E, Elgjo K,. Relationship of inflammatory bowel disease and primary sclerosing cholangitis. Semin Liver Dis. 1991; 11: 31-39.
22. Loftus EV Jr, Harewood GC, Loftus CG, et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut. 2005; 54: 91-96.